clinical trial · NCT06470763
A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)
Advanced Solid TumorANV600ANV600 + pembrolizumab (KEYTRUDA®)
brief summary
The purpose of study ANV600-001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, immunogenicity and antitumor activity of ANV600 administered as a single agent or in combination with pembrolizumab in adult participants with advanced solid tumors.
started
Jul 1, 2024
primary completion
Oct 1, 2027
completion
Feb 1, 2028
last updated
Apr 14, 2026
official title
A First-in-human, Open-label, Multicenter Phase I/II Study to Evaluate the Safety and Anti-tumor Activity of ANV600 as Single Agent and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol